Pharmaceutical thrombosis prevention in cardiovascular disease

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2002-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.11.4.553PMID 11922863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lamifiban

  2012cited by this paper
• Antiplatelet therapy for acute ischaemic stroke.

  2003cited by this paper
• Randomised, placebo-controlled trial

  2002cited by this paper
• αIIbβ3 and Its Antagonism at the New Millennium

  2001cited by this paper
• Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.

  2001cited by this paper
• Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions

  2001influential reference
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• ReoPro rules: results from the ‘Do Tirofiban and ReoPro Give Similar Efficacy Trial’ (TARGET)

  2001influential reference
• Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors

  2001cited by this paper
• Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty.

  2001influential reference
• All in the Family: Primary Megakaryocytes for Studies of Platelet αIIbβ3 Signaling

  2001cited by this paper
• A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study.

  2001cited by this paper
• Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

  2001cited by this paper
• Benefit of ADP Receptor Antagonists in Atherothrombotic Patients: New Evidence

  2001cited by this paper
• Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy

  2001cited by this paper
• Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

  2001influential reference
• Atherothrombosis: A Major Health Burden

  2001cited by this paper
• For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt

  2001cited by this paper
• Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood

  2001cited by this paper
• Platelet‐Fibrinogen Interactions

  2001influential reference
• P2y(12), a new platelet ADP receptor, target of clopidogrel.

  2001cited by this paper
• Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes

  2001cited by this paper
• Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes

  2001influential reference
• Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.

  2001cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper
• High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.

  2001cited by this paper
• Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

  2001cited by this paper
• Advances in the development of thrombin inhibitors

  2001cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• The P2Y 12 receptor as a therapeutic target in cardiovascular disease

  2001cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

  2001cited by this paper
• AlphaIIbbeta3 and its antagonism at the new millennium.

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity

  2000cited by this paper
• Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization.

  2000cited by this paper
• Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock

  2000cited by this paper
• Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.

  2000cited by this paper
• Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.

  2000cited by this paper
• Structure of basic phospholipase A2 from Agkistrodon halys Pallas: implications for its association, hemolytic and anticoagulant activities.

  2000cited by this paper
• Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?

  2000cited by this paper
• Current management of patients with pulmonary hypertension and right ventricular insufficiency

  2000cited by this paper
• Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

  2000cited by this paper
• Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.

  2000cited by this paper
• Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation.

  2000cited by this paper
• Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).

  2000cited by this paper
• Update on Abciximab Readministration During Percutaneous Coronary Interventions.

  2000cited by this paper
• GUSTO IV: expanding therapeutic options in acute coronary syndromes.

  2000cited by this paper
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.

  2000cited by this paper
• c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen: Implications for Myocardial Reperfusion Injury

  2000cited by this paper
• Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

  2000cited by this paper
• Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.

  2000cited by this paper
• A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.

  1999cited by this paper
• Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

  1999cited by this paper
• Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.

  1999cited by this paper
• The effects of two new antagonists of secretory PLA2 on TNF, iNOS, and COX-2 expression in activated macrophages.

  1999cited by this paper
• Small, noncovalent serine protease inhibitors

  1999cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.

  1999cited by this paper
• Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms.

  1999cited by this paper
• GP IIb/IIIa Antagonists

  1999cited by this paper
• Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study Investigators.

  1999cited by this paper
• Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat.

  1999cited by this paper
• Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa

  1999cited by this paper
• Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.

  1998cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998influential reference
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

  1998cited by this paper
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

  1998cited by this paper
• Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

  1998cited by this paper
• Snake venoms and the hemostatic system.

  1998cited by this paper
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

  1998cited by this paper
• Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes

  1998cited by this paper
• Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates.

  1998cited by this paper
• Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

  1998cited by this paper
• Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

  1998influential reference
• The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis

  1997cited by this paper
• The Regulation of Expression of Integrin Receptors

  1997cited by this paper
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.

  1997cited by this paper
• Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• New Antiplatelet Agents: Platelet GPIIb/llla Antagonists

  1995cited by this paper
• New antiplatelet agents: platelet GPIIb/IIIa antagonists.

  1995cited by this paper
• Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators.

  1995cited by this paper
• Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).

  1994cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy

  1994cited by this paper
• Importance of platelets in experimental venous thrombosis in the rat.

  1992cited by this paper
• Chemical cross-linking of arginyl-glycyl-aspartic acid peptides to an adhesion receptor on platelets.

  1988influential reference
• RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

  1988cited by this paper
• Secondary prevention of vascular disease by prolonged antiplatelet treatment

  1988cited by this paper
• Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor.

  1988influential reference
• Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation.

  1985cited by this paper
• HL-A AND INFECTIVE SACROILEITIS

  1974cited by this paper
• Perspectives Series: Cell Adhesion in Vascular Biology Platelet Gpiib/iiia Antagonists: the First Anti-integrin Receptor Therapeutics

  year unknowncited by this paper

• No citing papers are available for this paper.